Literature DB >> 9829349

Severe insulin resistance in a patient with type 1 diabetes and stiff-man syndrome treated with insulin lispro.

I B Hirsch1, D D'Alessio, L Eng, C Davis, A Lernmark, A Chait.   

Abstract

We describe a patient with type 1 diabetes with recurrent diabetic ketoacidosis and severe insulin resistance. Extensive evaluation of the etiology of the insulin resistance did not reveal an etiology, and well over 1000 U of daily insulin did not prevent the ketoacidosis. Her blood glucose and insulin requirements were improved with glucocorticoids and octreotide, but the effects of both of these agents were short-lived. She was given a trial of insulin lispro with immediate and dramatic effects, lowering her HbA1c from 14.6 to 5.1% in 7 months with a decrease in insulin requirements of 1600-100 U per day. Besides her diabetes, she had a history of pain and stiffness affecting numerous muscle groups, and hospitalization was required for pain control. The diagnosis of stiff-man syndrome (SMS) was confirmed with high titers of glutamic acid decarboxylase 65 antibodies in both serum and cerebral spinal fluid. In summary, we describe the first patient with type 1 diabetes, SMS, and severe insulin resistance. Although the etiology of the insulin resistance is unknown, due to the efficacious response to insulin lispro, hydrocortisone, and perhaps octreotide, we propose an immune-mediated etiology. Although rare, this syndrome needs to be considered as an etiology of insulin resistance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9829349     DOI: 10.1016/s0168-8227(98)00072-2

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  2 in total

1.  Inpatient care for stiff person syndrome in the United States: a nationwide readmission study.

Authors:  James A G Crispo; Dylan P Thibault; Yannick Fortin; Allison W Willis
Journal:  J Clin Mov Disord       Date:  2018-08-06

Review 2.  A new look at brittle diabetes.

Authors:  Irl B Hirsch; Linda M Gaudiani
Journal:  J Diabetes Complications       Date:  2020-06-02       Impact factor: 2.852

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.